Alnylam Pharmaceuticals (ALNY) Equity Ratio (2009 - 2026)

Alnylam Pharmaceuticals has reported Equity Ratio for 18 years, with the latest figure at 0.21 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 107.3% year-over-year to 0.21; the trailing twelve-month figure through Mar 2026 stood at 0.21 (up 107.3% YoY), and the FY2025 full-year result was 0.16, up 904.29% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.21, up from 0.16 in the prior quarter.
• The five-year high for Equity Ratio was 0.21 in Q1 2026, with the low at 0.12 in Q2 2023.
• Historically, Equity Ratio has averaged 0.02 across 5 years, with a median of 0.01 in 2024.
• Annual changes were most pronounced in 2023 — Equity Ratio sank 326.94% — and 2025, when it surged 7274.95%.
• Alnylam Pharmaceuticals' Equity Ratio stood at 0.04 in 2022, then declined by 29.13% to 0.06 in 2023, then soared by 127.46% to 0.02 in 2024, then surged by 904.29% to 0.16 in 2025, then jumped by 31.93% to 0.21 in 2026.
• The last three Equity Ratio figures came in at 0.21 (Q1 2026), 0.16 (Q4 2025), and 0.05 (Q3 2025), per Business Quant data.